Atlas Trials

CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII

Clinical trial NCT01454596 · COMPLETED

Trial details

NCT number
NCT01454596
Sponsor
National Cancer Institute (NCI)
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Malignant GliomaGlioblastomaBrain CancerGliosarcoma
Start date
2012-05-16
Primary completion
2018-11-01
Enrollment
18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.